These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15349011)

  • 1. Early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: a randomized, double-blind, placebo-controlled trial.
    Kotzailias N; Marker M; Jilma B
    J Clin Psychopharmacol; 2004 Oct; 24(5):536-9. PubMed ID: 15349011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paroxetine decreases platelet serotonin storage and platelet function in human beings.
    Hergovich N; Aigner M; Eichler HG; Entlicher J; Drucker C; Jilma B
    Clin Pharmacol Ther; 2000 Oct; 68(4):435-42. PubMed ID: 11061584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers: a randomized, placebo-controlled, double-blind trial.
    Kotzailias N; Andonovski T; Dukic A; Serebruany VL; Jilma B
    J Clin Pharmacol; 2006 Apr; 46(4):468-75. PubMed ID: 16554456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects.
    Booij J; de Jong J; de Bruin K; Knol R; de Win MM; van Eck-Smit BL
    J Nucl Med; 2007 Mar; 48(3):359-66. PubMed ID: 17332612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder.
    Bakish D; Cavazzoni P; Chudzik J; Ravindran A; Hrdina PD
    Biol Psychiatry; 1997 Jan; 41(2):184-90. PubMed ID: 9018388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.
    Farré M; Abanades S; Roset PN; Peiró AM; Torrens M; O'Mathúna B; Segura M; de la Torre R
    J Pharmacol Exp Ther; 2007 Dec; 323(3):954-62. PubMed ID: 17890444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine.
    Goldberg MR; Lowry RC; Musson DG; Birk KL; Fisher A; De Puy ME; Shadle CR
    J Clin Pharmacol; 1999 Feb; 39(2):192-9. PubMed ID: 11563413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism.
    Abdelmalik N; Ruhé HG; Barwari K; van den Dool EJ; Meijers JC; Middeldorp S; Büller HR; Schene AH; Kamphuisen PW
    J Thromb Haemost; 2008 Dec; 6(12):2168-74. PubMed ID: 18983505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men.
    Wilson S; Højer AM; Buchberg J; Areberg J; Nutt DJ
    J Psychopharmacol; 2015 Oct; 29(10):1085-91. PubMed ID: 26253622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of paroxetine and nefazodone on 5-HT1A receptor sensitivity.
    Sargent P; Williamson DJ; Pearson G; Odontiadis J; Cowen PJ
    Psychopharmacology (Berl); 1997 Aug; 132(3):296-302. PubMed ID: 9292630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects.
    Gerdelat-Mas A; Loubinoux I; Tombari D; Rascol O; Chollet F; Simonetta-Moreau M
    Neuroimage; 2005 Aug; 27(2):314-22. PubMed ID: 16019236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects.
    Loubinoux I; Pariente J; Rascol O; Celsis P; Chollet F
    Neuropsychologia; 2002; 40(11):1815-21. PubMed ID: 12062893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer.
    Loubinoux I; Tombari D; Pariente J; Gerdelat-Mas A; Franceries X; Cassol E; Rascol O; Pastor J; Chollet F
    Neuroimage; 2005 Aug; 27(2):299-313. PubMed ID: 15950492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder.
    Humble M; Bejerot S; Bergqvist PB; Bengtsson F
    Biol Psychiatry; 2001 Feb; 49(4):360-8. PubMed ID: 11239907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline.
    Waldinger MD; Hengeveld MW; Zwinderman AH; Olivier B
    J Clin Psychopharmacol; 1998 Aug; 18(4):274-81. PubMed ID: 9690692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers.
    Blier P; Saint-André E; Hébert C; de Montigny C; Lavoie N; Debonnel G
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):41-50. PubMed ID: 16690005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
    Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
    Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects.
    Röschke J; Kögel P; Schlösser R; Wagner P; Mann K; Rossbach W; Benkert O
    Psychopharmacology (Berl); 1997 Jul; 132(1):44-9. PubMed ID: 9272758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute subjective responses to paroxetine in normal volunteers.
    Brauer LH; Rukstalis MR; de Wit H
    Drug Alcohol Depend; 1995 Oct; 39(3):223-30. PubMed ID: 8556971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.